Dabrafenib and Trametinib in Patients With Tumors With <i>BRAF^V600E</i> Mutations: Results of the NCI-MATCH Trial Subprotocol H

Abstract

This study met its primary end point, with an ORR of 38% (<i>P</i> < .0001) in this mixed histology, pretreated cohort. This promising activity warrants additional investigations in <i>BRAF^V600</i>-mutated tumors outside of currently approved indications.